Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination.

BACKGROUND Telomerase is an enzyme essential for the normal replication of chromosomes. Telomerase activity is absent in most somatic cells in adults, but it is usually expressed in cancer cells, including ovarian carcinoma cells. Our principal goal was to compare the sensitivity of a telomerase assay, i.e., the telomeric repeat amplification protocol (TRAP) assay, with that of cytologic examination in detecting cancer cells in the peritoneal cavity of patients with ovarian carcinoma. METHODS TRAP assays and cytologic examinations were performed on peritoneal washings and ascitic fluids from 42 patients with active ovarian carcinoma. Control specimens included washings from 29 patients with benign ovarian diseases and ascitic fluids from 14 patients with liver failure. We also evaluated the stability of telomerase in ascitic fluids left unprocessed at room temperature as well as the ability of the TRAP assay to detect cancer cells in mixtures containing large numbers of normal cells. RESULTS Specimens from 37 (88%) of the 42 patients with ovarian carcinoma tested positive for telomerase. Cytologic examination detected cancer cells in only 27 of the telomerase-positive specimens (i.e., in specimens from 64% of the 42 patients). This difference of 24% (95% confidence interval = 17%-30%) in sensitivity between the two tests was statistically significant (two-sided P = .002). Specimens from five of the patients with ovarian carcinoma were cytologically negative and telomerase negative. All 43 control specimens were cytologically negative, but the TRAP assay detected telomerase in two of them. Telomerase activity was detected in unprocessed samples left at room temperature for 5 days and in mixtures containing a small number of cancer cells and a 2000- to 10000-fold excess of normal cells. CONCLUSIONS Assaying for telomerase is more sensitive than cytologic examination in detecting cancer cells in the peritoneal cavity of patients with ovarian carcinoma.

[1]  J. Felix,et al.  Telomerase activity in benign and malignant epithelial ovarian tumors. , 1997, Journal of the National Cancer Institute.

[2]  J. Califano,et al.  Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. , 1996, Cancer research.

[3]  David Sidransky,et al.  Microsatellite alterations in serum DNA of head and neck cancer patients , 1996, Nature Medicine.

[4]  A. Kurt,et al.  Microsatellite alterations in plasma DNA of small cell lung cancer patients , 1996, Nature Medicine.

[5]  H. Erdjument-Bromage,et al.  A Human Telomeric Protein , 1995, Science.

[6]  V A Zakian,et al.  Telomeres: Beginning to Understand the End , 1995, Science.

[7]  P. Conti,et al.  Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. , 1995, Cancer treatment reviews.

[8]  M. S. Rhyu.  Telomeres, telomerase, and immortality. , 1995, Journal of the National Cancer Institute.

[9]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[10]  D. Sidransky,et al.  Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.

[11]  Y S Erozan,et al.  Microsatellite alterations as clonal markers for the detection of human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Harley,et al.  Telomerase activity in human ovarian carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Schlom,et al.  Coordinate elevation of serum markers in ovarian cancer but not in benign disease , 1991 .

[14]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[15]  A. Sherrod,et al.  Culture of human fetal ovarian epithelium in a chemically-defined, serum-free medium: a model for ovarian carcinogenesis. , 1990, Anticancer research.

[16]  L. Dubeau,et al.  Detection of ras point mutations by polymerase chain reaction using mutation-specific, inosine-containing oligonucleotide primers. , 1989, Biochemical and biophysical research communications.

[17]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[18]  W. J. Dixon,et al.  Introduction to Statistical Analysis , 1951 .

[19]  R. Bast,et al.  Coordinate elevation of serum markers in ovarian cancer but not in benign disease. , 1991, Cancer.